NVD - Novadel Pharma Inc

[kbrown57]

This looks like new news but I could be wrong.

http://quotwantcaring.blog.migranci....el-pharma-inc/

[kold00]

anyone think this is a good buy at .25?

[kbrown57]

Originally Posted by kold00

anyone think this is a good buy at .25?

Company has lots of potential they are just having difficulty in this economy getting the FDA approved product to market. I have some money in NVD because you never know if/when that news might come out. One of my penny longs but you have to make do your own DD and decide for yourself.

[duvaldg]

Up to .30 today.

NovaDel Article Published in Headache: The Journal of Head and Face Pain

NovaDel Pharma Inc. (NYSE AMEX: NVD) announced that an article titled "Rapid Oral Transmucosal Absorption of Sumatriptan, and Pharmacodynamics in Acute Migraine" was published online on June 22, 2009 in the peer-reviewed journal Headache: The Journal of Head and Face Pain. NovaDel conducted two clinical trials evaluating sumatriptan administered via its oral spray drug delivery technology. The objectives of the trials were: (1) To determine whether sumatriptan can be absorbed across the oral mucosa, and, if so; then (2) to describe its pharmacokinetics; and (3) to investigate whether there are pharmacodynamic correlates of such pharmacokinetics in patients experiencing migraine attacks.

The first clinical trial, in normal volunteers, compared the pharmacokinetic performance of a lingual spray (LS) formulation of sumatriptan (2 dose sizes, one of which in both the fed and fasted state) with a 50-mg sumatriptan tablet. The second clinical trial, in a patient population enriched by documenting suboptimal response to an initial 50-mg sumatriptan tablet, was a multiple-attack, crossover, fixed dose-order, open-label comparison of sumatriptan administered by LS (up to 3 different dose sizes) and a 100-mg sumatriptan tablet.

The LS formulations resulted in double-peaked time-plasma concentration curves that are consistent with absorption of sumatriptan across the oral mucosa. The first "Tmax" was usually about 10-15 minutes. In the enriched patient population, this corresponded with evidence of earlier efficacy for the LS in comparison with a 50-mg tablet; the lower dose size for the former was consistent with oral mucosal drug absorption, and evasion of first-pass metabolism.

The initial pharmacokinetics of LS approximate to those of a subcutaneous injection, albeit some fraction of these doses is also swallowed. These pharmacokinetics correspond with earlier effectiveness of LS in comparison with a 50-mg sumatriptan tablet, and at lower dose, in an enriched, relevant patient population.

Results of this study were previously announced in a press release dated September 4, 2008. The initial studies support further development of this innovative formulation of sumatriptan and this new route of administration. Dr. David Bergstrom, NovaDel's COO, indicated "We are encouraged by the results of these studies in providing a new potential treatment option for the very debilitating condition of migraine attacks."

[kbrown57]

http://www.marketwatch.com/story/nov...27?siteid=nbsh

NovaDel Licenses its NitroMist® Lingual Spray to Mist
FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc., (NYSE AMEX: NVD) has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris. Under terms of the agreement, Mist will pay NovaDel a $1,000,000 licensing fee upon execution of the agreement, milestone payments totaling an additional $1,000,000 over the next twelve months and ongoing performance payments of seventeen percent (17%) of net sales.

Through a separate license agreement with Mist, Akrimax Pharmaceuticals, LLC will receive the exclusive right to manufacture, distribute, market and sell NitroMist® in North America. NitroMist® provides acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. The lingual spray form of the drug is conveniently administered and is rapidly absorbed into the bloodstream via the oral mucosa, providing patients a fast and tolerable treatment option for the prevention or relief of pain associated with such attacks.

“Akrimax’s focus on metabolic diseases and its leadership’s proven experience launching successful products and companies makes it an ideal partner to launch this innovative therapy,” said Steven B. Ratoff, NovaDel’s Chairman and Interim CEO. “We’re delighted to have Akrimax leveraging its manufacturing expertise and progressive commercial platform to optimize the value of NitroMist®,” he added.

“NitroMist® offers an important practical innovation in the delivery of a life support medicine for cardiovascular patients suffering from angina,” stated Alan L. Rubino, CEO and President of Akrimax. “We are extremely enthusiastic to be introducing and commercializing NitroMist® as this new product is an excellent complement to our developing cardiovascular and metabolic portfolio.”

ABOUT NOVADEL PHARMA

NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. The Company’s proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly reduced first pass liver metabolism, which may result in lower doses. Oral sprays eliminate the requirement for water or the need to swallow, potentially improving patient convenience and adherence.

NovaDel’s oral spray technology is focused on addressing unmet medical needs for a broad array of existing and future pharmaceutical products. The Company’s most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. NovaDel plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. To find out more about NovaDel Pharma Inc. (NYSE AMEX: NVD), visit our website at www.novadel.com.

ABOUT AKRIMAX PHARMACEUTICALS, LLC

Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated next-generation specialty pharmaceutical company that acquires, markets and develops products to address disease states related to metabolic diseases. The company also owns a world-class manufacturing plant in Rouses Point, NY with a highly skilled workforce. The plant encompasses 67.6 acres with 38 buildings, offering approximately 1 million sq. feet of manufacturing and packaging space. Akrimax was formed in 2007 and purchased the Rouses Point plant from Wyeth in January 2008.

Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products including Inderal®LA and LoOvral®-28.

[Fink]

Yulp thats the deal with all these R&D pharma companies. They make for a great play up to the FDA approvals, but without a marketing partner the PPS goes no where. They also get the king of all shorts after the FDA appronal announcements.
I just got spammed this stock and taking a look. Partnerships and 10Q rreports are what will get this up and rolling.
Looking to get in below .24. Definitly below .26

They remind me of a small Pharma company down Soth in Alabama, ProEthics. fast absorbtion type drugs under the tongue and all. Was bought up by some Korean company. This stuff sells. They had a migrane, heart meds and a few cough meds.

[Fink]

Originally Posted by kold00

anyone think this is a good buy at .25?

Kold00 Bump for you man! Great call. Just dumoped @ morning high and buying back in on the pull back. I see it as a runner the next few days


They got the thumbs up this AM


And thank You God! I almost pulled the trigger on CHBO yesterday @ EOD, but stepped back and wanted to sleep on it

I'm riding NVD for a few days and rolling a bunch into IMGG if it pulls back from the latest CC pr.

[Fink]

Originally Posted by sonixtwo

It was nice to see the volume back up today. It did very well considering the market overall.

I dumped 2,000 shares at $0.35. Still holding on to 5,000, hoping for that pop!

Do you think it has the MoMo to break .35?

[SeeMiYah]

NovaDel Receives Notice of Allowance for New U.S. Patent Covering its Oral Spray Drug Delivery Technology

Nov. 5, 2009 (Business Wire) -- NovaDel Pharma Inc. (NYSE AMEX: NVD), today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology. Once issued, this patent will expire in 2018.

As previously announced, NovaDel’s Zolpimist ™ (zolpidem tartrate) 5 mg and 10 mg Oral Spray product is approved by the U.S. Food and Drug Administration (FDA) for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpimist is NovaDel’s second product approved by the FDA that uses NovaDel’s proprietary NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien®, the world’s leading sedative hypnotic for the treatment of insomnia.

NovaDel maintains an extensive worldwide portfolio of intellectual property rights for select compounds using its pioneering oral spray delivery system. Upon issuance of the application, the Company will have been granted nine patents in the U.S., three patents in Canada and 66 patents throughout Europe, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden and Switzerland. Additionally, NovaDel has over 80 patents pending around the globe.

http://app.quotemedia.com/quotetools...l&webmasterId=

[duvaldg]

hit 35 but didn't hold it. Still not a bad day.